Bristol-Myers Squibb stock rated highly based on fundamentals and valuation

From Nasdaq: 2025-03-17 09:07:45

Validea’s guru fundamental report for BRISTOL-MYERS SQUIBB CO (BMY) rates it highest using the Multi-Factor Investor model based on Pim van Vliet’s strategy. BMY is a large-cap value stock in the Biotechnology & Drugs industry with a rating of 87% based on its fundamentals and valuation. The stock meets some of the strategy’s tests, but falls short in others. Pim van Vliet, head of Conservative Equities at Robeco Asset Management, created this strategy that seeks low volatility stocks with strong momentum and high net payout yields. This approach aims to provide high returns with less risk.



Read more at Nasdaq: Validea Detailed Fundamental Analysis – BMY